Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast. Sales of ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

A high-resolution spatial map of the human hypothalamus makes it possible to identify specific cells, determine their exact ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

The nonclinical pharmacokinetic (PK) and pharmacodynamic (PD) study was conducted to examine the effects of semaglutide ...

AgelessRx, a pioneer in longevity and telehealth solutions, announced the introduction of oral sublingual drops for GLP-1 receptor agonists Semaglutide and Tirzepatide. By offering non-injectable ...

Fitness and nutrition gurus like to make weight loss sound easy. But in reality, it’s often incredibly tough to incorporate ...

Northstrive Biosciences announced an update for its obesity treatment candidates, EL-22 and EL-32, both aimed at optimizing fat loss while ...

Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...